Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Atara Biotherapeutics (ATRA) reported a Q4 loss of $1.19 per share, which was better than the Zacks Consensus Estimate of a $3.82 loss. This is an improvement from the $14 per share loss a year ago.
March 07, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atara Biotherapeutics reported a Q4 loss of $1.19 per share, better than the expected $3.82 loss, showing significant improvement from last year's $14 loss per share.
The better-than-expected earnings report is likely to positively impact ATRA's stock price in the short term. The significant improvement from last year's loss also adds to investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100